Improved risk prediction of chemotherapy‐induced neutropenia—model development and validation with real‐world data-Reference-Cited by-同舟云学术

Improved risk prediction of chemotherapy‐induced neutropenia—model development and validation with real‐world data

Published:2021-12-03 Issue:3 Volume:11 Page:654-663
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Venäläinen Mikko S.¹^ORCID,Heervä Eetu²³,Hirvonen Outi²⁴⁵,Saraei Sohrab¹,Suomi Tomi¹,Mikkola Toni⁶,Bärlund Maarit⁷⁸^ORCID,Jyrkkiö Sirkku²,Laitinen Tarja⁹¹⁰,Elo Laura L.¹¹¹^ORCID

Affiliation:

1. Turku Bioscience Centre University of Turku and Åbo Akademi University Turku Finland

2. Department of Oncology Turku University Hospital and FICAN West Turku Finland

3. University of Turku Turku Finland

4. Department of Clinical Oncology University of Turku Turku Finland

5. Palliative Center Turku University Hospital Turku Finland

6. Tays Research Services Clinical Informatics Team Tampere University Hospital and University of Tampere Tampere Finland

7. Department of Oncology Tays Cancer Centre Tampere University Hospital Tampere Finland

8. Faculty of Medicine and Health Technology Tampere University Tampere Finland

9. Department of Pulmonary Medicine University of Turku and Turku University Hospital Turku Finland

10. Administration Center Tampere University Hospital and University of Tampere Tampere Finland

11. Institute of Biomedicine University of Turku Turku Finland

Funder

Sigrid Juséliuksen Säätiö

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4465

Reference28 articles.

1. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

2. Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in breast cancer patients;Renner P;Cochrane Database of Systematic Reviews,2012

3. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study

4. Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study

5. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of peri-chemotherapy hematological parameters for febrile neutropenia in patients with cancer;Frontiers in Oncology;2024-08-19

2. Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy;Cancer Investigation;2024-07-04

3. Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning;Expert Review of Anti-infective Therapy;2024-03-08

4. Identification of small cell lung cancer patients who are at risk of developing common serious adverse event groups with machine learning;Frontiers in Drug Safety and Regulation;2023-09-15

5. Development of prediction model for alanine transaminase elevations during the first 6 months of conventional synthetic DMARD treatment;Scientific Reports;2023-08-09